Ratings Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.14 ^USD	+0.14%		+4.39%	+5.78%

Mar. 18	Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	MT
Mar. 18	Fulcrum Therapeutics, Inc. Announces Executive Changes	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
FULCRUM THERAPEUTICS, INC.	+5.78%	444M	D+
IQVIA HOLDINGS INC.	+1.51%	42.75B	B
LONZA GROUP AG	+49.22%	41.61B	A
MODERNA, INC.	+8.57%	41.34B	B-
CELLTRION, INC.	-12.36%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B	B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+6.35%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes